Vermillion Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Vermillion Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.6K	Hold	1,000	–	–	﹤0.01%	1009
2026 Q1	$19K	Buy	1,000 +496	+98%	+$8.02K	0.01%	306
2025 Q4	$8.81K	Hold	504	–	–	﹤0.01%	397
2025 Q3	$10.4K	Hold	504	–	–	﹤0.01%	1056
2025 Q2	$10.7K	Hold	504	–	–	0.01%	331
2025 Q1	$9.72K	Sell	504 -504	-50%	-$10.1K	﹤0.01%	943
2024 Q4	$18K	Buy	+1,008	New	+$19.5K	0.01%	268

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vermillion Wealth Management's SMMT Position: Q2 2026 in Review

Vermillion Wealth Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 1,000 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1009.

Vermillion Wealth Management first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $19K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Vermillion Wealth Management held 1,000 shares of Summit Therapeutics worth $14.6K as of Q2 2026.
Vermillion Wealth Management left its Summit Therapeutics share count unchanged in Q2 2026.
Summit Therapeutics made up ﹤0.01% of Vermillion Wealth Management's portfolio in Q2 2026, its #1009 holding.
Vermillion Wealth Management first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
Vermillion Wealth Management's Summit Therapeutics position peaked at $19K in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.